The nutrition management of the patient with acute renal failure

Journal of Parenteral and Enteral Nutrition

Volumn 20, Issue 1, 1996, Pages 3-12

  Kopple, Joel D ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; CATABOLISM; CONFERENCE PAPER; DIETARY INTAKE; ELECTROLYTE DISTURBANCE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FUNCTION; METABOLIC REGULATION; NUTRITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; UREA NITROGEN BLOOD LEVEL;

ANIMALIA;

EID: 0030061953     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/014860719602000103     Document Type: Conference Paper

References (70)

1. Kjellstrand CM, Ebben J, Davin T: Time of death, recovery of renal function, development of chronic renal failure and need for chronic hemodialysis in patients with acute tubular necrosis. Trans Am Soc Artif Organ 27:45-50, 1981
2. Butkus DE: Persistent high mortality in acute renal failure. Are we asking the right questions? Arch Intern Med 143:209-212, 1983
3. Feinstein EI, Blumenkrantz MJ, Healy M, et al: Clinical and metabolic responses to parenteral nutrition in acute renal failure. A controlled double-blind study. Medicine 60:124-137, 1981
4. Feinstein EI, Kopple JD, Silberman H, et al: Total parenteral nutrition with high or low nitrogen intakes in patients with acute renal failure. Kidney Int 24 (Suppl 16):S319-323, 1983
5. Kopple JD, Jones MR, Keshaviah PR, et al: A proposed glossary for dialysis kinetics. Am J Kid Dis 26:963-981, 1995
6. Gotch FA: Kinetic modeling in hemodialysis. IN Clinical Dialysis, 2nd ed, Nissenson AR, Fine RN. Gentile DE (eds). Appleton & Lange, Norwalk CT, 1990, pp 118-146
7. Grodstein G, Kopple JD: Urea nitrogen appearance, a simple and practical indicator of total nitrogen output (Abstr). Kidney Int 16:953, 1979
8. Maroni B, Steinman T, Mitch W: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58-65, 1985
9. Gao XL, Kopple JD: Relationship between dietary protein, urea nitrogen appearance (UNA) and total nitrogen appearance (TNA) in patients with chronic renal failure (CRF) (Abstr). J Am Soc Neph 5:491, 1995
10. Leonard CD, Luke RG, Siegel RR: Parenteral essential amino acids in acute renal failure. Urology 6:154-157, 1975
11. Cahill GF Jr: Starvation in man. N Engl J Med 282:668-675, 1970
12. Kopple JD, Feinstein EI: Nutritional therapy for patients with acute renal failure. IN Advances in Clinical Nutrition, Johnston IDA (ed). MTP Press Limited, Lancaster, PA. 1982, pp 113-122
13. Abel RM, Beck CH Jr, Abott WM, et al: Improved survival and acute renal failure after treatment with intravenous essential L-amino acids and glucose. Results of a prospective, double-blind study. N Engl J Med 288:695, 1973
14. Mirtallo JM, Schneider PJ, Mavko K, et al: A comparison of essential and general amino acid infusions in the nutritional support of patients with compromised renal function. JPEN 6:109-113, 1982
15. Motil KJ, Harmon WE, Grupe WE: Complications of essential amino acid hyperalimentation in children with acute renal failure. JPEN 4:32-35, 1980
16. Nakasaki H, Katayama T, Yokoyama S, et al: Complication of parenteral nutrition composed of essential amino acids and histidine in adults with renal failure. JPEN 17:86-90, 1993
17. Swendseid ME, Harris CL, Tuttle SG: The effect of sources of nonessential nitrogen on nitrogen balance in young adults. J Nutr 71:105-108, 1960
18. Anderson HL, Heindel MB, Linkswile H: Effect on nitrogen balance of adult man of varying source of nitrogen and level of calorie intake. J Nutr 99:82-90, 1969
19. Laidlaw SA, Kopple JD: Newer concepts of the indispensable amino acids. Am J Clin Nutr 46:593-605, 1987
20. VanVenrooij WJW, Henshaw EC, Hirsch CA: Effects of deprival of glucose or individual amino acids on polyribosome distribution and rate of protein synthesis in cultured mammalian cells. Biochem Biophys Acta 259:127-137, 1972
21. Buse MG, Reid SS: Leucine a possible regulator of protein turnover in muscle. J Clin Invest 56:1250-1261, 1975
22. Kopple JD, Swendseid ME, Shinaberger JH, et al: The free and bound amino acids removed by hemodialysis. Trans Am Soc Artif Intern Organs 19:309-313, 1973
23. Wolfson M, Jones MR, Kopple JD: Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 21:500-506, 1982
24. Ikazler TA, Flakoll PJ, Parker RA, et al: Amino acid and albumin losses during hemodialysis. Kidney Int 46:830-837, 1994
25. Chazot C, Shahmir E, Matias B, et al: Provision of amino acids by dialysis during maintenance hemodialysis (MHD) (Abstr). J Am Soc Nephrol 6:574, 1995
26. Davenport A, Roberts NB: Amino acid losses during continuous highflux hemofiltration in the critically ill patient. Crit Care Med 17:1010-1014, 1989
27. Davies SP, Reaveley DA, Brown EA, et al: Amino acid clearances and daily losses in patients with acute renal failure treated by continuous arteriovenous hemodialysis. Crit Care Med 19:1510-1515, 1991
28. Mehta RL: Therapeutic alternatives to renal replacement for critically ill patients in acute renal failure. Semin Nephrol 14:64-82, 1994
29. Hollenberg NK, Epstein M, Rosen SM, et al: Acute oliguric renal failure in man: Evidence for preferential renal cortical ischemia. Medicine 47:455-474, 1968
30. Hollenberg NK, Adams DF, Oken DE, et al: Acute renal failure due to nephrotoxins: Renal hemodynamic and angiographic studies in man. N Engl J Med 282:1329-1334, 1970
31. Solez K, Morel-Maroger L, Sraer J: The morphology of "acute tubular necrosis" in man: Analysis of 57 renal biopsies and comparison with the glycerol model. Medicine 58:362-376, 1979
32. Kelleher SP, Robinette JB, Miller F, et al: Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure. Kidney Int 31:725-730, 1987
33. Chima CS, Meyer L, Hummell AC, et al: Protein catabolic rate in patients with acute renal failure on continuous arteriovenous hemofiltration and total parenteral nutrition. J Am Soc Nephrol 3:1516-1521, 1993
34. Bellomo R, Mansfield D, Rumble S, et al: A comparison of conventional dialytic therapy and acute continuous hemodiafjltration in the management of acute renal failure in the critically ill. Renal Failure 15:595-602, 1993
35. Hakim RM, Wingard RL, Parker RA: Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 331:1338-1342, 1994
36. Souba WW, Herskowitz K, Augsten TR, et al: Glutamine nutrition: Theoretical considerations and therapeutic impact. JPEN 14 (Suppl):237S-243S, 1990
37. Ziegler TR, Young LS, Benfell K, et al: Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 116:821-828, 1992
38. Barbul A: Arginine: Biochemistry, physiology and therapeutic implications. JPEN 10:227-238, 1986
39. Gianotti L, Alexander JW, Pyles T, et al: Arginine-supplemented diets improve survival in gut-derived sepsis and peritonitis by modulating bacterial clearance. Ann Surg 217:644-654, 1993
40. Schloerb PR, Amare M: Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (A randomized, double-blind study). JPEN 17:407-413, 1993
41. Schramm L, Heidbreder E, Schmitt A, et al: Role of L-arginine-derived NO in ischemic acute renal failure in the rat. Renal Failure 16:555-569, 1994
42. Kopple .JD: Dietary considerations in patients with advanced chronic renal failure, acute renal failure, and transplantation. IN Diseases of the Kidney, 5th ed, Schrier RW, Gottschalk CW (eds). Little Brown and Company, Boston, 1992, pp 3167-3210
43. Ponting GA, Teale JD, Halliday D, et al: Postoperative positive nitrogen balance with intravenous hyponutrition and growth hormone. Lancet 1:438-440, 1988
44. Wilmore DW: Catabolic illness. Strategies for enhancing recovery. N Engl J Med 325:695-702, 1991
45. Ziegler TR, Lazarus JM, Young LS, et al: Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 2:1130-1135, 1991
46. Kopple JD: The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure. Mineral Electrolyte Metab 18:269-275, 1992
47. Schulman G, Wingard RL, Hutchison RL, et al: The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Kid Dis 21:527-534, 1993
48. Dahn MS, Lange MP, Jacobs LA: Insulin-like growth factor 1 production is inhibited in human sepsis. Arch Surg 123:1409-1414, 1988
49. Moats-Staats BM, Brady JL Jr. Underwood LE, et al: Dietary protein restriction in artificially reared neonatal rats causes a reduction of insulin-like growth factor 1 gene expression. Endocrinology 120:2368-2374, 1989
50. Guler H-P: Insulin-like growth factor 1 and insulin: What is the difference? An overview of in vivo studies. IN Modern Concepts of Insulin-Like Growth Factors, Spencer EM (ed). Elsevier, NY, 1991 pp 583-590
51. Guler H-P, Zapf J, Scherwiller E, et al: Recombinant human insulin-like growth factor 1 stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 85:4889-4893, 1988
52. O'Sullivan U, Gluckman PD, Breier BH, et al: Insulin-like growth factor 1 (IGF-1) in mice reduces weight loss during starvation. Endocrinology 125:2793-2794, 1989
53. Fagin JA, Melmed S: Relative increase in IGF-1 messenger ribonucleic acid levels in compensatory renal hypertrophy. Endocrinology 120:718-724, 1987
54. Guler H-P, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137-140, 1987
55. Guler H-P, Schmid C, Zapf J, et al Effects of recombinant insulin-like growth factor 1 on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 86:2868-2872, 1989
56. Jacob R, Barrett E, Plewe G, et al: Acute effects of insulin-like growth factor 1 on glucose and amino acid metabolism in awake fasted rat. J Clin Invest 83:1717-1723, 1989
57. Hirschberg R, Kopple JD: Evidence that insulin-like growth factor I increases renal plasma flow and GFR in fasted rats. J Clin Invest 83:326-330, 1989
58. Hirschberg R, Brunori G, Kopple JD, et al: Effects of insulin-like growth factor 1 on renal function in normal men. Kidney Int 43:387-397, 1992
59. Ding H, Kopple J, Cohen A, et al: Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 91:2281-2287, 1993
60. Miller SB, Martin DR, Kissane J, et al: Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat. Proc Natl Acad Sci USA 89:11876-11880, 1992
61. Lin J-J, Cybulsky AV, Goodyer PR, et al: Insulin-like growth factor-1 enhances epidermal growth factor receptor activation and renal tubular cell regeneration in postischemic acute renal failure. J Lab Clin Med 125:724-733, 1995
62. Clark R, Mortensen D, Rabkin R: Recovery from acute ischaemic renal failure is accelerated by des (1-3) insulin-like growth factor-1. Clin Sci 86:709-714, 1994
63. Humes HD, Cieslinski DA, Coimbra TM, et al: Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 84:1757-1761, 1989
64. Miller SB, Martin DR, Kissane J, et al: Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats. Am J Physiol 266:F129-134, 1994
65. Rahman SN, Kim GE, Mathew AS, et al: Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 45:1731-1738, 1994
66. Solomkin JS, Fink MP: Very large-scale, randomized, clinical trials in sepsis and septic shock. Crit Care Med 22:1-2, 1994
67. Fisher CJ Jr, Dhainaut J-F A, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836-1843, 1994
68. McCloskey RV, Straube RC, Sanders C, et al: The CHESS Trial Study Group: Treatment of septic shock with human monoclonal antibody HAIA. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 121:1-5, 1994
69. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1102, 1991
70. Pennington JE: Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 17 (Suppl 2):S515-S519, 1993